|
|
|
|
|
Highlights from the 2023 American Urological Association Annual Meeting
|
|
|
|
|
|
|
| AUA Guidelines: Upper Tract Urothelial Carcinoma (UTUC)
|
| Jonathan A. Coleman, MD
|
| Jonathan Coleman presents the first iteration of the AUA/SUO guidelines for the diagnosis and management of non-metastatic upper tract urothelial carcinoma (UTUC).
|
|
|
|
|
|
| Panel Discussion: Management of Upper Tract Urothelial Carcinoma
|
| Jay Raman, MD, FACS, Tomonori Habuchi, MD, and Sima Porten, MD, MPH, FACS
|
| Surena Matin moderates a panel discussion with Jay Raman, Tomonori Habuchi, and Sima Porten as panelists discussing a case presentation of an 85-year-old female with painless gross hematuria for 6 months. This patient was found to have a 3 cm right distal ureteral tumor with hydronephrosis. This patient underwent a biopsy with total laser ablation, with no other tumors seen.
|
|
|
|
|
|
|
|
| An Adaptable Approach: Is JELMYTO Appropriate Across Low-Grade UTUC Presentations and Practice Patterns? |
| Jennifer A. Linehan, MD and Sandip Prasad, MD, MPHil |
| Jennifer Linehan and Sandip Prasad discuss the utility, efficacy, and safety of JELMYTO across low-grade upper tract urothelial carcinoma (UTUC) presentations and practice patterns, using adaptable patient and physician-centered approaches. |
|
|
|
|
|
| Bladder Cancer: Epidemiology & Evaluation II
|
|
| Agent Orange Exposure and Risk of Bladder Cancer: A Nationwide Cohort Study
|
| Stephen B. Williams, MD
|
| In the largest case matched study among Vietnam Veterans to date, there was an increased risk of bladder cancer, but not bladder cancer aggressiveness, among Agent Orange exposed Veterans, though the increased risk was small. These findings suggest a link between Agent Orange exposure and risk of bladder cancer, though the clinical relevance of this is unclear.
|
|
|
|
|
|
| Bladder Cancer: Invasive I
|
|
| The Tolerability and Efficacy of BCG Administration after Recurrence in Bladder-Preserving Therapy For Muscle-Invasive Bladder Cancer
|
| Ruiyang Xie, MD
|
| Ruiyang Xie presents work evaluating the tolerability and efficacy of BCG administration after recurrence in bladder-preserving therapy for muscle-invasive bladder cancer. Based on the data, the tolerability and efficacy of BCG instillations for patients with NIMBC recurrence post-TMT is acceptable and similar to those observed with high-risk NMIBC patients from the EORTC cohort.
|
|
|
|
|
|
| Avelumab First-line (1L) Maintenance for Advanced Urothelial Carcinoma: Long-Term Outcomes From JAVELIN Bladder 100 in Subgroups Defined by Response to 1L Chemotherapy
|
| Shilpa Gupta, MD
|
| Shilpa Gupta presents the long-term outcomes from JAVELIN Bladder 100, which evaluated avelumab first-line maintenance for advanced urothelial carcinoma. This report included subgroup analysis stratified by the response to 1st line chemotherapy.
|
|
|
|
|
|
| The Immune-Related Adverse Events Paradox in Locally Advanced or Metastatic Urothelial Cancer Patients Receiving Atezolizumab: Analysis of Individual Participant Data From IMvigor210 and IMvigor211 |
| Daniele Robesti, MD |
| Daniele Robesti presents the results of a pooled analysis of individual participant data from IMvigor210 and IMvigor211 evaluating the immune-related adverse events paradox in locally advanced or metastatic urothelial cancer patients receiving atezolizumab. |
|
|
|
|
|
|
|
|
|
|
| The Use of 68Ga-FAP-2286 PET Imaging in Patients with Localized Bladder Cancer |
| Domenique Escobar, MD |
Domenique Escobar presents the results of the analysis evaluating the use of 68Ga-FAP-2286 PET imaging in patients with localized bladder cancer. Given the limitations of currently available imaging modalities (i.e., CT, MRI, FDG-PET) for bladder cancer staging, there is an urgent need for advances in imaging technology to ensure accurate staging and treatment.
|
|
|
|
|
|
| Bladder Cancer: Invasive III
|
|
| Understanding the Impact of the Social Construct of Race on Receipt of Radical Cystectomy in the Largest Equal Access Health System in the US: The Veterans Affairs Health System |
| Danny Long |
| Danny Long evaluates the impact of race on the receipt of radical cystectomy within the VA Healthcare system. The Veterans Affairs Health System is the large equal access health care system in the United States. As such, much of the impact of socioeconomic status on healthcare delivery is mitigated. They chose to use this system to evaluate the receipt of radical cystectomy for patients with muscle invasive bladder cancer, as it is guideline recommended treatment. |
|
|
|
|
|
 |
